Browsing: Clinical Trials & R&D

Prolynx obesity drugs aim to use novel linker technology for monthly or quarterly administration, backed by a $70M Series A funding.

Novartis Ianalumab Success marks a significant achievement in treating immune thrombocytopenia, impacting low platelet counts.

Tecvayli multiple myeloma data presented at ASH suggests potential for early use in treatment, involving 165 patients.

Tern leukemia drug shows potential at ASH Conference, challenging Novartis’ Scemblix with promising early results.

Dyne Duchenne drug approval could challenge Sarepta’s Exondys 51, impacting the market and offering new clinical insights.

Lilly Jaypirca trial demonstrates efficacy comparable to Imbruvica with safety advantages, potentially altering leukemia and lymphoma treatment.

Pharvaris Phase 3 Success marks a significant milestone in hereditary angioedema treatment, potentially impacting over 8,000 patients in Europe.

Janux prostate cancer data reveals a lower response rate, impacting its clinical trial progress.

Protego amyloidosis drug receives $130M funding to develop a new treatment for light chain amyloidosis, aiming to improve patient outcomes.

Belite Stargardt drug shows promising results in Phase 3 trial, positioning it for potential market approval.